1. Home
  2. |Insights
  3. |NIST Publishes Assessment Procedures for Enhanced Security Controls Used to Protect CUI

NIST Publishes Assessment Procedures for Enhanced Security Controls Used to Protect CUI

Client Alert | 1 min read | 03.18.22

The National Institute of Standards and Technology (NIST) recently published final assessment procedures for the enhanced security controls used to protect particularly sensitive forms of controlled unclassified information (CUI) from sophisticated adversaries.  NIST SP 800-172A, Assessing Enhanced Security Requirements for Controlled Unclassified Information, articulates procedures and methods to assess contractor implementation of the 35 enhanced security controls found in NIST SP 800-172, Enhanced Security Requirements for Protecting Controlled Unclassified Information: A Supplement to NIST Special Publication 800-171.  The publication can be used to conduct first, second, and third-party assessments with varying degrees of rigor based on the assessor’s desired level of assurance.

The enhanced controls and corresponding assessment procedures are expected to impact contractors handling CUI associated with critical programs and high value assets.  The Department of Defense (DoD) also plans to incorporate the requirements from NIST SP 800-172 into Level 3 of the Cybersecurity Maturity Model Certification (CMMC)  The assessment procedures and methods in NIST SP 800-172A are expected to inform the government-led assessments needed for DoD contractors to achieve certification at CMMC Level 3. 

Contacts

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...